Myriagon is developing a completely novel class of analgesics to help patients suffering from neuropathic pain, in particular chemotherapy-induced neuropathic pain — a debilitating and often dose-limiting side effect of cancer treatment. Current off-label therapies have limited effect and frequently cause sedation, tolerance, or dependence. Myriagon’s first-in-class peripherally restricted MAGL inhibitors show strong pain-reducing effects in preclinical models without affecting the central nervous system.
The jury — comprised of Carine van den Brink (Axon Lawyers), Geert-Jan Mulder (Forbion), Thom Frielink (Curie Capital), Eric van der Aa (Pivot Park) and Bert-Jan Haijema (3DPharmXchange) — was highly impressed by Myriagon’s work.
They praised the team’s strong scientific rationale, clear understanding of clinical need, and compelling pitch. The jury also highlighted the team’s long-term vision and the significant unmet need they are addressing, with millions of patients worldwide affected by neuropathic pain with limited effective treatment options.
Myriagon is led by Mirjam Huizenga and Wouter Driever, who are developing next-generation pain therapeutics designed to be more effective and safer than existing treatments. Their approach aims to radically improve the quality of life for patients living with neuropathic pain.
Leiden, 8 January 2026 – Two scientific projects from Leiden University and LUMC have received funding from Open Science NL. The aim is to make science more accessible to...
[Amsterdam, 15th December 2025] — Nikon BioImaging Lab Europe (NBIL) is delighted to announce that it has been honoured with the prestigious Deshima Award in the “Newcomer”...
The publication of the Wennink Report has led to extensive national and regional media coverage on the role of red biotechnology in the future of the Dutch economy and healthcare...